tiprankstipranks
Theralase Reports Decline in 2Q2024 Revenue
Company Announcements

Theralase Reports Decline in 2Q2024 Revenue

Story Highlights

Theralase Technologies (TSE:TLT) has released an update.

Don't Miss Our Christmas Offers:

Theralase Technologies Inc., a company focused on developing treatments for cancer and other diseases, has published its unaudited financial results for the first half of 2024, showing a decline in total revenue by 35% and a net loss reduction of 6%. A conference call to discuss these results is scheduled for August 21, 2024.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands US Bladder Cancer Study Sites
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Clinical Trial for Bladder Cancer
TipRanks Canadian Auto-Generated NewsdeskTheralase Expands Cancer Study with Promising Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App